BACKGROUND: The polymorphic family of killer-cell immunoglobulin-like receptors (KIRs) consists of activating and inhibitory receptors expressed by natural killer (NK) cells and effector T cells that recognize human leukocyte antigen (HLA) class I ligands. It has been suggested that KIR/HLA incompatibility exerts beneficial effects in hematopoietic stem cell transplantation. METHODS: To elucidate whether certain receptor-ligand combinations between recipient KIR and donor HLA antigens lead to enhanced alloreactivity of NK cells associated with acute rejection (aRx) after kidney transplantation, we analyzed the entirety of matches/mismatches between KIR genes and known HLA ligands for aRx patients (n=105) compared to patients with stable renal function (n=119). RESULTS: Whereas HLA-C ligand incompatibility between donor and recipient has no influence on aRx, grafts derived from donors homozygous for HLA-C group 2 alleles seem to demonstrate a better outcome (P=0.052). Additionally, a higher number of inhibitory receptors in the recipient's genotype (P=0.042), a significant higher number of matches for the receptors KIR2DL2/DS2 (P=0.004), as well as a higher number of mismatches for KIR2DL3 (P=0.014) could be observed for patients with stable renal function. CONCLUSION: Our data illustrate that certain KIR/HLA class I ligand combinations between donor and recipient might influence graft short-term outcome after renal transplantation.
BACKGROUND: The polymorphic family of killer-cell immunoglobulin-like receptors (KIRs) consists of activating and inhibitory receptors expressed by natural killer (NK) cells and effector T cells that recognize human leukocyte antigen (HLA) class I ligands. It has been suggested that KIR/HLA incompatibility exerts beneficial effects in hematopoietic stem cell transplantation. METHODS: To elucidate whether certain receptor-ligand combinations between recipient KIR and donor HLA antigens lead to enhanced alloreactivity of NK cells associated with acute rejection (aRx) after kidney transplantation, we analyzed the entirety of matches/mismatches between KIR genes and known HLA ligands for aRxpatients (n=105) compared to patients with stable renal function (n=119). RESULTS: Whereas HLA-C ligand incompatibility between donor and recipient has no influence on aRx, grafts derived from donors homozygous for HLA-C group 2 alleles seem to demonstrate a better outcome (P=0.052). Additionally, a higher number of inhibitory receptors in the recipient's genotype (P=0.042), a significant higher number of matches for the receptors KIR2DL2/DS2 (P=0.004), as well as a higher number of mismatches for KIR2DL3 (P=0.014) could be observed for patients with stable renal function. CONCLUSION: Our data illustrate that certain KIR/HLA class I ligand combinations between donor and recipient might influence graft short-term outcome after renal transplantation.
Authors: Trent M Prall; Michael E Graham; Julie A Karl; Roger W Wiseman; Adam J Ericsen; Muthuswamy Raveendran; R Alan Harris; Donna M Muzny; Richard A Gibbs; Jeffrey Rogers; David H O'Connor Journal: Immunogenetics Date: 2017-03-25 Impact factor: 2.846
Authors: S Vendelbosch; M de Boer; K van Leeuwen; F Pourfarzad; J Geissler; T K van den Berg; T W Kuijpers Journal: Genes Immun Date: 2014-12-11 Impact factor: 2.676
Authors: J R Greenland; N P Jewell; M Gottschall; N N Trivedi; J Kukreja; S R Hays; J P Singer; J A Golden; G H Caughey Journal: Am J Transplant Date: 2014-02-11 Impact factor: 8.086
Authors: Maneesh K Misra; Danillo G Augusto; Gonzalo Montero Martin; Neda Nemat-Gorgani; Jürgen Sauter; Jan A Hofmann; James A Traherne; Betsy González-Quezada; Clara Gorodezky; Will P Bultitude; Wesley Marin; Cynthia Vierra-Green; Kirsten M Anderson; Antonio Balas; Jose L Caro-Oleas; Elisa Cisneros; Francesco Colucci; Ravi Dandekar; Sally M Elfishawi; Marcelo A Fernández-Viña; Merhan Fouda; Rafael González-Fernández; Arend Große; Maria J Herrero-Mata; Sam Q Hollenbach; Steven G E Marsh; Alex Mentzer; Derek Middleton; Ashley Moffett; Miguel A Moreno-Hidalgo; Ghada I Mossallam; Annettee Nakimuli; Jorge R Oksenberg; Stephen J Oppenheimer; Peter Parham; Maria-Luiza Petzl-Erler; Dolores Planelles; Florentino Sánchez-García; Francisco Sánchez-Gordo; Alexander H Schmidt; John Trowsdale; Luciana B Vargas; Jose L Vicario; Carlos Vilches; Paul J Norman; Jill A Hollenbach Journal: Hum Immunol Date: 2018-10-12 Impact factor: 2.850
Authors: Cornelia Fabritius; Paul Viktor Ritschl; Thomas Resch; Mario Roth; Susanne Ebner; Julia Günther; Vanessa Mellitzer; Anh-Vu Nguyen; Johann Pratschke; Martina Sauter; Karin Klingel; Katja Kotsch Journal: Am J Transplant Date: 2017-09-09 Impact factor: 8.086